[ET Net News Agency, 6 July 2026] Morgan Stanley lowered the target price for WuXi XDC (02268) to HKD80 from HKD83 and maintained the "overweight" rating.
The research house said with the consolidation of BioDlink in 2Q26, it cuts 2026-30 earnings estimates by ~0-7%, factoring in lower GM and incremental finance expenses. (rc)
The research house said with the consolidation of BioDlink in 2Q26, it cuts 2026-30 earnings estimates by ~0-7%, factoring in lower GM and incremental finance expenses. (rc)